🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-520631-17-00
Authorised Phase I

A Study to Assess the Safety of RG6496 in Huntington’s Disease Gene Expansion Carriers with the Selected Genetic Variant (POINT-HD)

2025-520631-17-00 · tracked via the Priya Life Science EU tracker
Sponsor
F. Hoffmann-La Roche AG
Sponsor type
Pharmaceutical company
Therapeutic area
Nervous System Diseases
Decision date
11/05/2026
Enrollment target
43
Sites
Italy, Poland, Denmark, Germany, Portugal, Spain

Condition studied

Huntington’s Disease Gene Expansion Carriers

Eligibility

Age group
18-64 years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-520631-17-00 on CTIS ↗ ← All trials in the EU